MYCN and neuroblastoma: Interestingly, our recent studies have shown that chronic treatment of N-MYC-amplified NB cells with etoposide does not modify the homozygous p53 mutation (A161T), previously found in etoposide-sensitive NB cells, and therefore, in this context, p53 is responsible neither for OXPHOS activation nor for the metabolic adaptation of etoposide-resistant NB cells [67].